Webinar
UPCOMING! Exploring the application of deterministically programmed hiPSCs to advance early-stage drug discovery
Explore real-world applications of bit.bio’s ioCells across early drug discovery, from target ID to toxicology.
Explore real-world applications of bit.bio’s ioCells across early drug discovery, from target ID to toxicology.
In drug discovery, researchers need reliable, ready-to-use human cell models that deliver reproducible results at every stage of the workflow. Hear experts as they present data on the application of bit.bio’s deterministically programmed human iPSC-derived ioCells across key drug discovery stages. Through case studies and real-world applications, you will learn how these cells and the associated protocols support workflows in target identification, assay development, disease modelling, and toxicology.
Key learning points
- Discover quick and easy generation of gene knockouts and CRISPR screens for target ID and validation in human iPSC-derived neurons and microglia using CRISPR-Ready ioCells
- Learn about assay development in neuroinflammation and demyelinating diseases using neuronal and glial co-cultures
- Explore rapidly maturing, consistent human iPSC-derived disease models for neurodegenerative disorders such as Huntington’s and Alzheimer’s disease
- See data for predicting drug-induced liver injury in toxicology studies with new human iPSC-derived liver models
Date
26th Aug 2025
Time
8am PDT | 11am EDT | 4pm BST | 5pm CEST